Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:
”Genomic testing for all patients considered for clopidogrel (before therapy starts). UK.
Clopidogrel empirically prescribed by doctors is not working in a staggering 29% of patients – being in those ineffective in prevention of stroke or MI.
Why: being a prodrug it must be activated via CYP 2C19 — patients with loss‑of‑function these CYP variants (intermediate/poor metabolisers) get much less antiplatelet effect and more thrombotic events.
So: the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics issued a guideline that recommends CYP2C19 genotyping for all patients in whom clopidogrel is being considered, “where testing is available”.
My opinion, this means that testing will soonly be available in secondary care units across the UK.
Moreover: the PGx (pharmacogenomics) data is stored as structured data into the shared electronic health record, information readily available to the prescribers (hospital, GP/community systems).
This way it will be a once in a lifetime test.
Looks quite futuristic for a patent-expired medicine.”
Quoting University of Liverpool‘s post:
”NEWS I: New UK guideline for clopidogrel recommends pharmacogenetic testing for all patients before prescription
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
Find out more here.”
Read the full article here.
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration